Zhongshan Ligao Biopharmaceutical Co., Ltd

A single-center, open-label, randomized, single-dose, two-period, two-sequence, crossover bioequivalence study was conducted to evaluate the bioequivalence of the test preparation ursodeoxycholic acid tablets (strength: 50 mg) and the reference preparation ursodeoxycholic acid tablets (URSO®, strength: 50 mg) in healthy adult subjects under fasting and fed conditions.